Supernus Pharmaceuticals | SUPN - مصاريف البيع والإدارة





مصاريف البيع والإدارة تغيير تاريخ
Abbott USD 3.27B 138M 2026-03
ANI Pharmaceuticals USD 73.66M 9.14M 2026-03
Aurora Cannabis CAD 40.62M 1.17M 2025-12
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Canopy Growth CAD 28.9M 636K 2025-12
Cara Therapeutics USD 2.19M 2.45M 2025-09
Corcept Therapeutics USD 128.04M 13.3M 2026-03
Eisai JPY 119.54B 7.82B 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Novo Nordisk DKK 13.22B 4.22B 2026-03
Pacira USD 83.88M 7.99M 2026-03
Perrigo USD 267.3M 11.4M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Supernus Pharmaceuticals USD 118.23M 4.16M 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Xeris Pharmaceuticals USD 42.64M 3.82M 2025-12